Home

Novo Nordisk A/S Common Stock (NVO)

51.96
+3.86 (8.03%)
NYSE · Last Trade: Dec 23rd, 12:16 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close48.10
Open52.67
Bid51.95
Ask51.96
Day's Range51.75 - 53.20
52 Week Range43.08 - 93.80
Volume43,978,048
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield2.198 (4.23%)
1 Month Average Volume17,182,884

Chart

About Novo Nordisk A/S Common Stock (NVO)

Novo Nordisk A/S is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals, primarily in the fields of diabetes care and hormone replacement therapy. With a strong emphasis on research and development, the company aims to improve the lives of patients with chronic conditions by providing high-quality medications and medical devices. Novo Nordisk is recognized for its comprehensive approach to diabetes management, including insulin products and modern delivery systems, while also expanding its portfolio to address other serious conditions, such as obesity and rare blood disorders. The company operates in numerous countries, combining expertise in biotechnology with a commitment to sustainability and corporate responsibility. Read More

News & Press Releases

The Incretin Empire: Eli Lilly’s (LLY) Path to a $1 Trillion Market Cap and Beyond
As of December 22, 2025, the global equity markets are witnessing a historic recalibration of the healthcare sector. For decades, the "Trillion Dollar Club" was an exclusive enclave for Silicon Valley’s technology elite—Apple, Microsoft, and Nvidia. However, the narrative shifted decisively in November 2025 when Eli Lilly and Company (NYSE: LLY) breached the $1 trillion [...]
Via PredictStreet · December 22, 2025
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare sector during the peak of the COVID-19 crisis, the pharmaceutical giant is currently navigating one of the most challenging chapters in its [...]
Via PredictStreet · December 22, 2025
The Weight of a Trillion: Inside Eli Lilly’s Pharmaceutical Hegemony
On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold earlier this year, Lilly has transcended the traditional boundaries of a "Big Pharma" company to become a high-growth technology-like play on human longevity and [...]
Via PredictStreet · December 18, 2025
Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pillstocktwits.com
Via Stocktwits · December 23, 2025
Thin Trading and High Hopes: Markets Eye a 'Santa Claus Rally' as 2025 Draws to a Close
As the sun sets on a volatile but ultimately record-breaking year, Wall Street has entered its final, holiday-shortened trading week of 2025. With the S&P 500 sitting at a historic peak of 6,904 as of December 23, investors are closely watching for the emergence of the "Santa Claus
Via MarketMinute · December 23, 2025
Santa Claus Rally Solidifies as S&P 500 Secures Third Consecutive Winning Session Amid Economic Resilience
The U.S. equity markets continued their year-end ascent on Tuesday, December 23, 2025, as the S&P 500 (INDEXSP:.INX) notched its third consecutive winning session. This momentum, often referred to as the "Santa Claus Rally," was fueled by a confluence of robust economic data and a growing sense
Via MarketMinute · December 23, 2025
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The primary driver of this turnaround has been the resolution of long-standing pricing uncertainties, as most major drugmakers
Via MarketMinute · December 23, 2025
These stocks are gapping in today's sessionchartmill.com
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · December 23, 2025
Nasdaq, S&P 500 Futures Tread Caution Ahead Of GDP, Confidence Data: Why NVO, ZIM, SIDU Are On Traders' Radar Todaystocktwits.com
Via Stocktwits · December 23, 2025
Novo Nordisk Stock Soars After Hours As FDA Greenlights Wegovy Pill For Weight Lossstocktwits.com
The Danish drugmaker expects to launch the pill in the U.S. in January.
Via Stocktwits · December 22, 2025
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?fool.com
Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.
Via The Motley Fool · December 22, 2025
Novo Nordisk (NYSE:NVO) Identified as a 'Decent Value' Stock with Strong Fundamentalschartmill.com
Novo Nordisk (NVO) presents a value opportunity, trading at a discount to peers with top-tier profitability and solid financial health.
Via Chartmill · December 20, 2025
2026 Market Outlook: Key Themes and Predictions
As the final weeks of 2025 draw to a close, the global financial landscape is entering a pivotal transformation. The "AI Gold Rush" that defined the previous two years is evolving from a speculative frenzy into a disciplined era of monetization and operational efficiency. Simultaneously, a unique confluence of fiscal
Via MarketMinute · December 19, 2025
Prediction: 1 Healthcare Giant Set to Soar in 2026fool.com
Novo Nordisk has struggled this past year, but its beaten-down valuation has made it a bargain buy today.
Via The Motley Fool · December 18, 2025
Better Buy in 2026: Novo Nordisk or Intuitive Surgical?fool.com
These struggling healthcare stocks haven't said their last words.
Via The Motley Fool · December 18, 2025
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordiskfool.com
These two healthcare stocks have strong growth prospects, but they've been going in opposite directions.
Via The Motley Fool · December 18, 2025
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall Street's expectations. The announcement immediately sent shockwaves through the market, with Pfizer's stock experiencing a notable decline as investors
Via MarketMinute · December 16, 2025
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Issued on behalf of Avant Technologies Inc.
By USA News Group · Via GlobeNewswire · December 16, 2025
Pfizer Adds to Its Big Bet on Weight Loss Drugsmarketbeat.com
Via MarketBeat · December 16, 2025
Eli Lilly Just Delivered Fantastic News to Investorsfool.com
Eli Lilly shares have climbed in the double digits this year.
Via The Motley Fool · December 15, 2025
Profit Powerhouse: Strong Earnings Outlook Defies Market Slips, Signaling Continued Bull Run for US Stocks
Despite recent pockets of volatility and "slips" in the U.S. stock market during late 2025, a robust corporate profit outlook is emerging as a powerful counter-narrative, fueling investor optimism and suggesting that still-higher prices for American equities may be on the horizon. While the Cboe Volatility Index (VIX) saw
Via MarketMinute · December 16, 2025
2 Predictions for Novo Nordisk in 2026fool.com
The company's worst days might be behind it.
Via The Motley Fool · December 14, 2025
My Top 10 Stocks to Buy for 2026fool.com
These players are well-positioned to potentially gain next year -- and over time.
Via The Motley Fool · December 13, 2025
Why Novo Nordisk Stock Topped the Market on Thursdayfool.com
A proposed new federal law could provide some competitive guardrails for the company's most important product.
Via The Motley Fool · December 11, 2025
Navigating Nuance: Tech Innovation, Healthcare Revival, and Energy's Evolving Landscape Shape Late 2025 Markets
As December 2025 unfolds, global financial markets are characterized by a delicate balance of cautious optimism and persistent uncertainty. A "Santa Claus rally" sentiment prevails, fueled by expectations of central bank easing and a surprisingly resilient, albeit slowing, global economy. While the technology sector continues its role as a primary
Via MarketMinute · December 11, 2025